The tumour glyco-code as a novel immune checkpoint for immunotherapy

Nature Reviews Immunology

Volumn 18, Issue 3, 2018, Pages 204-211

  Rodríguez, Ernesto ^a   Schetters, Sjoerd T T ^a   Van Kooyk, Yvette ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GLYCAN; GLYCOSYLTRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; LECTIN; LECTIN RECEPTOR; LEUKOSIALIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; N ACETYLGALACTOSAMINYLTRANSFERASE; PROGRAMMED DEATH 1 RECEPTOR; THERATOPE; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; PDCD1 PROTEIN, HUMAN; POLYSACCHARIDE; TUMOR PROTEIN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTE DIFFERENTIATION; METASTASIS; METASTATIC BREAST CANCER; NATURAL KILLER CELL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROCEDURES; T LYMPHOCYTE; TUMOR ESCAPE;

GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; LECTINS; NEOPLASM PROTEINS; NEOPLASMS; POLYSACCHARIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85042610128     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2018.3     Document Type: Review

References (74)

1. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
2. McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613-628 (2017).
3. Blank, C. U., Haanen, J. B., Ribas, A. & Schumacher, T. N. The "cancer immunogram". Science 352, 658-660 (2016).
4. Chen, D. S. & Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1-10 (2013).
5. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
6. Varki, A. Since there are PAMPs and DAMPs, there must be SAMPs Glycan "self-associated molecular patterns" dampen innate immunity, but pathogens can mimic them. Glycobiology 21, 1121-1124 (2011).
7. van Kooyk, Y. & Rabinovich, G. A. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9, 593-601 (2008).
8. Cagnoni, A. J., Perez Saez, J. M., Rabinovich, G. A. & Marino, K. V. Turning-off signaling by siglecs, selectins, and galectins: chemical inhibition of glycan-dependent interactions in cancer. Front. Oncol. 6, 109 (2016).
9. Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15, 540-555 (2015).
10. Koike, T. et al. Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc. Natl Acad. Sci. USA 101, 8132-8137 (2004).
11. Radhakrishnan, P. et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc. Natl Acad. Sci. USA 111, E4066-E4075 (2014).
12. Ju, T. & Cummings, R. D. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437, 1252 (2005).
13. Gill, D. J. et al. Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proc. Natl Acad. Sci. USA 110, E3152-E3161 (2013).
14. Nguyen, A. T. et al. Organelle specific O-glycosylation drives MMP14 activation, tumor growth, and metastasis. Cancer Cell 32, 639-653. e6 (2017).
15. van Gisbergen, K. P., Aarnoudse, C. A., Meijer, G. A., Geijtenbeek, T. B. & van Kooyk, Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res. 65, 5935-5944 (2005).
16. Gringhuis, S. I. et al. Fucose-based PAMPs prime dendritic cells for follicular T helper cell polarization via DC-SIGN-dependent IL-27 production. Nat. Commun. 5, 5074 (2014).
17. Garcia-Vallejo, J. J. et al. CNS myelin induces regulatory functions of DC-SIGN-expressing, antigen-presenting cells via cognate interaction with MOG. J. Exp. Med. 211, 1465-1483 (2014).
18. van Vliet, S. J. et al. MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-alpha secretion. J. Leukoc. Biol. 94, 315-323 (2013).
19. van Vliet, S. J., Gringhuis, S. I., Geijtenbeek, T. B. & van Kooyk, Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat. Immunol. 7, 1200-1208 (2006).
20. Lenos, K. et al. MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. Oncotarget 6, 26278-26290 (2015).
21. Macauley, M. S., Crocker, P. R. & Paulson, J. C. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14, 653-666 (2014).
22. Perdicchio, M. et al. Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells. Oncotarget 7, 8771-8782 (2016).
23. Perdicchio, M. et al. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells. Proc. Natl Acad. Sci. USA 113, 3329-3334 (2016).
24. Julien, S., Videira, P. A. & Delannoy, P. Sialyl-tn in cancer: (how) did we miss the target Biomolecules 2, 435-466 (2012).
25. Carrascal, M. A. et al. Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol. Oncol. 8, 753-765 (2014).
26. Beatson, R. et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat. Immunol. 17, 1273-1281 (2016).
27. Jandus, C. et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest. 124, 1810-1820 (2014).
28. Li, C. W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).
29. Mendez-Huergo, S. P., Blidner, A. G. & Rabinovich, G. A. Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis. Curr. Opin. Immunol. 45, 8-15 (2017).
30. Toscano, M. A. et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8, 825-834 (2007).
31. Ilarregui, J. M. et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10, 981-991 (2009).
32. Rubinstein, N. et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5, 241-251 (2004).
33. Tsuboi, S. et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30, 3173-3185 (2011).
34. Dardalhon, V. et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J. Immunol. 185, 1383-1392 (2010).
35. Vlad, A. M. et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 196, 1435-1446 (2002).
36. Apostolopoulos, V. et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl Acad. Sci. USA 100, 15029-15034 (2003).
37. Vogt, G. et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat. Genet. 37, 692-700 (2005).
38. Malaker, S. A. et al. Identification of glycopeptides as posttranslationally modified neoantigens in leukemia. Cancer Immunol. Res. 5, 376-384 (2017).
39. Amin, R. et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood 126, 1911-1920 (2015).
40. Hollander, N. & Haimovich, J. Altered N-linked glycosylation in follicular lymphoma and chronic lymphocytic leukemia: involvement in pathogenesis and potential therapeutic targeting. Front. Immunol. 8, 912 (2017).
41. Kaur, S., Kumar, S., Momi, N., Sasson, A. R. & Batra, S. K. Mucins in pancreatic cancer and its microenvironment. Nat. Rev. Gastroenterol. Hepatol. 10, 607-620 (2013).
42. Drake, R. R. Glycosylation and cancer: moving glycomics to the forefront. Adv. Cancer Res. 126, 1-10 (2015).
43. Kailemia, M. J. et al. Recent advances in the mass spectrometry methods for glycomics and cancer. Anal. Chem. 90, 208-224 (2018).
44. Drake, R. R. et al. MALDI mass spectrometry imaging of N-linked glycans in cancer tissues. Adv. Cancer Res. 134, 85-116 (2017).
45. Kunzke, T. et al. Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome. Oncotarget 8, 68012-68025 (2017).
46. Stadlmann, J. et al. Comparative glycoproteomics of stem cells identifies new players in ricin toxicity. Nature 549, 538-542 (2017).
47. Cummings, R. D. The haystack is full of needles: Technology rescues sugars! Mol. Cell 68, 827-829 (2017).
48. Kim, J. et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci. Transl Med. 9, eaah5583 (2017).
49. Gilgunn, S., Conroy, P. J., Saldova, R., Rudd, P. M. & O'Kennedy, R. J. Aberrant PSA glycosylation-a sweet predictor of prostate cancer. Nat. Rev. Urol. 10, 99-107 (2013).
50. Yang, A. P. et al. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer. Clin. Chim. Acta 437, 183-186 (2014).
51. Tiernan, J. P. et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br. J. Cancer 108, 662-667 (2013).
52. Campos, D. et al. Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery. Mol. Cell Proteomics 14, 1616-1629 (2015).
53. Syed, P. et al. Role of lectin microarrays in cancer diagnosis. Proteomics 16, 1257-1265 (2016).
54. Gill, D. J., Chia, J., Senewiratne, J. & Bard, F. Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J. Cell Biol. 189, 843-858 (2010).
55. Ashkani, J. & Naidoo, K. J. Glycosyltransferase gene expression profiles classify cancer types and propose prognostic subtypes. Sci. Rep. 6, 26451 (2016).
56. Agrawal, P. et al. A systems biology approach identifies FUT8 as a driver of melanoma metastasis. Cancer Cell 31, 804-819. e7 (2017).
57. Dube, D. H. & Bertozzi, C. R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4, 477-488 (2005).
58. Miles, D. & Papazisis, K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer 3 (Suppl. 4), S134-S138 (2003).
59. Miles, D. et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16, 1092-1100 (2011).
60. Xiao, H., Woods, E. C., Vukojicic, P. & Bertozzi, C. R. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc. Natl Acad. Sci. USA 113, 10304-10309 (2016).
61. Bull, C. et al. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol. Cancer Ther. 12, 1935-1946 (2013).
62. Jennewein, M. F. & Alter, G. Immunoregulatory roles of antibody glycosylation. Trends Immunol. 38, 358-372 (2017).
63. Posey, A. D. Jr. et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44, 1444-1454 (2016).
64. Tacken, P. J., de Vries, I. J., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802 (2007).
65. Unger, W. W. et al. Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. Oncoimmunology 4, e970462 (2015).
66. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321-330 (2017).
67. Lisacek, F. et al. Databases and Associated Tools for Glycomics and Glycoproteomics. Methods Mol. Biol. 1503, 235-264 (2017).
68. Varki, A. et al. Essentials of Glycobiology (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2009).
69. Gould, S. E., Junttila, M. R. & de Sauvage, F. J. Translational value of mouse models in oncology drug development. Nat. Med. 21, 431-439 (2015).
70. Day, C. P., Merlino, G. & Van Dyke, T. Preclinical mouse cancer models: A maze of opportunities and challenges. Cell 163, 39-53 (2015).
71. Garcia-Vallejo, J. J. & van Kooyk, Y. The physiological role of DC-SIGN: A tale of mice and men. Trends Immunol. 34, 482-486 (2013).
72. Costache, M. et al. Evolution of fucosyltransferase genes in vertebrates. J. Biol. Chem. 272, 29721-29728 (1997).
73. Varki, A. Uniquely human evolution of sialic acid genetic and biology. Proc. Natl ACad. Sci. USA 107 (Suppl. 2), 8939-8946 (2010).
74. Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).